Top

Published in:

01-10-2013

YWHAE/14-3-3ε: a potential novel genetic risk factor and CSF biomarker for HIV neurocognitive impairment

Authors: Diana Morales, Rosa Hechavarria, Valerie Wojna, Summer F. Acevedo

Published in: Journal of NeuroVirology | Issue 5/2013

Abstract

YWHAE (14-3-3ε) protein levels are considered to be a reliable biomarker for neurodegeneration. The YWHAE protein interacts both directly and indirectly with human immunodeficiency virus (HIV) accessory proteins, leading to cell death. The purpose of this study was to examine the relationship between YWHAE polymorphisms and HIV-associated neurocognitive disorder (HAND) and the relationship between YWHAE protein levels and HAND. A cross-sectional study using random samples of HIV-seropositive (n = 20) and HIV-seronegative (controls) (n = 16) women from the Hispanic-Latino Longitudinal Cohort of Women was conducted. Individuals who are HIV-seropositive and heterozygous at the rs4790084/rs1204828 loci in the YWHAE gene were 3× more likely to display reduced cognitive functioning, to have received a HAND diagnosis, and to have less YHWAE protein expressed than homozygotes. Western blots from cerebral spinal fluid indicate that the HIV-seropositive women with HAND expressed 4.5× less YWHAE compared to HIV-seropositive cognitively normal women (94 % sensitivity, 84 % specificity; HIV-seropositive vs. controls). Therefore, polymorphism in YWHAE may be a genetic risk factor for HAND and levels of YWHAE protein are a likely biomarker for neurocognitive status in HIV-seropositive women.

Aitken A, Jones D, Soneji Y, Howell S (1995) 14-3-3 proteins: biological function and domain structure. Biochem Soc Trans 23:605–611PubMed

American Academy of Neurology AIDS Task Force (1991) Nomenclature and research case definitions for neurologic manifestations of human immunodeficiency virus-type 1 (HIV-1) infection. Report of a Working Group of the American Academy of Neurology AIDS Task Force. Neurology 41:778–785CrossRef

American Academy of Neurology AIDS Task Force (1996) Clinical confirmation of the American Academy of Neurology algorithm for HIV-1-associated cognitive/motor disorder. The Dana Consortium on Therapy for HIV Dementia and Related Cognitive Disorders. Neurology 47:1247–1253CrossRef

Berg D, Holzmann C, Riess O (2003) 14-3-3 proteins in the nervous system. Nat Rev Neurosci 4:752–762PubMedCrossRef

Boesenberg-Grosse C, Schulz-Schaeffer WJ, Bodemer M, Ciesielczyk B, Meissner B, Krasnianski A, Bartl M, Heinemann U, Varges D, Eigenbrod S, Kretzschmar HA, Green A, Zerr I (2006) Brain-derived proteins in the CSF: do they correlate with brain pathology in CJD? BMC Neurol 6:35PubMedCrossRef

Bolton DL, Barnitz RA, Sakai K, Lenardo MJ (2008) 14-3-3 theta binding to cell cycle regulatory factors is enhanced by HIV-1 Vpr. Biol Direct 3:17PubMedCrossRef

Che XH, Chen H, Xu ZM, Shang C, Sun KL, Fu WN (2010) 14-3-3epsilon contributes to tumour suppression in laryngeal carcinoma by affecting apoptosis and invasion. BMC Cancer 10:306PubMedCrossRef

Cohen J (1988) Statistical power analysis for the behavioral sciences, 2nd edn. Lawrence Erlbaum, Hillsdale, NJ

Cohen EA, Terwilliger EF, Jalinoos Y, Proulx J, Sodroski JG, Haseltine WA (1990) Identification of HIV-1 vpr product and function. J Acquir Immune Defic Syndr 3:11–18PubMed

Collins SJ, Sanchez-Juan P, Masters CL, Klug GM, van Duijn C, Poleggi A, Pocchiari M, Almonti S, Cuadrado-Corrales N, de Pedro-Cuesta J, Budka H, Gelpi E, Glatzel M, Tolnay M, Hewer E, Zerr I, Heinemann U, Kretszchmar HA, Jansen GH, Olsen E, Mitrova E, Alperovitch A, Brandel JP, Mackenzie J, Murray K, Will RG (2006) Determinants of diagnostic investigation sensitivities across the clinical spectrum of sporadic Creutzfeldt–Jakob disease. Brain 129:2278–2287PubMedCrossRef

Gardino AK, Yaffe MB (2011) 14-3-3 proteins as signaling integration points for cell cycle control and apoptosis. Semin Cell Dev Biol 22:688–695PubMedCrossRef

Gelman BB, Nguyen TP (2010) Synaptic proteins linked to HIV-1 infection and immunoproteasome induction: proteomic analysis of human synaptosomes. J Neuroimmune Pharmacol 5:92–102PubMedCrossRef

Geschwind MD, Martindale J, Miller D, DeArmond SJ, Uyehara-Lock J, Gaskin D, Kramer JH, Barbaro NM, Miller BL (2003) Challenging the clinical utility of the 14-3-3 protein for the diagnosis of sporadic Creutzfeldt–Jakob disease. Arch Neurol 60:813–816PubMedCrossRef

He J, Choe S, Walker R, Di Marzio P, Morgan DO, Landau NR (1995) Human immunodeficiency virus type 1 viral protein R (Vpr) arrests cells in the G2 phase of the cell cycle by inhibiting p34cdc2 activity. J Virol 69:6705–6711PubMed

Heaton RK, Clifford DB, Franklin DR Jr, Woods SP, Ake C, Vaida F, Ellis RJ, Letendre SL, Marcotte TD, Atkinson JH, Rivera-Mindt M, Vigil OR, Taylor MJ, Collier AC, Marra CM, Gelman BB, McArthur JC, Morgello S, Simpson DM, McCutchan JA, Abramson I, Gamst A, Fennema-Notestine C, Jernigan TL, Wong J, Grant I (2010) HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy: CHARTER study. Neurology 75:2087–2096PubMedCrossRef

Hsich G, Kenney K, Gibbs CJ, Lee KH, Harrington MG (1996) The 14-3-3 brain protein in cerebrospinal fluid as a marker for transmissible spongiform encephalopathies. N Engl J Med 335:924–930PubMedCrossRef

Ikeda M, Hikita T, Taya S, Uraguchi-Asaki J, Toyo-oka K, Wynshaw-Boris A, Ujike H, Inada T, Takao K, Miyakawa T, Ozaki N, Kaibuchi K, Iwata N (2008) Identification of YWHAE, a gene encoding 14-3-3epsilon, as a possible susceptibility gene for schizophrenia. Hum Mol Genet 17:3212–3222PubMedCrossRef

Iskander S, Walsh KA, Hammond RR (2004) Human CNS cultures exposed to HIV-1 gp120 reproduce dendritic injuries of HIV-1-associated dementia. J Neuroinflammation 1:7PubMedCrossRef

Kapasi AA, Fan S, Singhal PC (2001) Role of 14-3-3epsilon, c-Myc/Max, and Akt phosphorylation in HIV-1 gp 120-induced mesangial cell proliferation. Am J Physiol Renal Physiol 280:F333–F342PubMed

Kino T, Pavlakis GN (2004) Partner molecules of accessory protein Vpr of the human immunodeficiency virus type 1. DNA Cell Biol 23:193–205PubMedCrossRef

Kino T, De Martino MU, Charmandari E, Ichijo T, Outas T, Chrousos GP (2005a) HIV-1 accessory protein Vpr inhibits the effect of insulin on the Foxo subfamily of forkhead transcription factors by interfering with their binding to 14-3-3 proteins: potential clinical implications regarding the insulin resistance of HIV-1-infected patients. Diabetes 54:23–31PubMedCrossRef

Kino T, Gragerov A, Valentin A, Tsopanomihalou M, Ilyina-Gragerova G, Erwin-Cohen R, Chrousos GP, Pavlakis GN (2005b) Vpr protein of human immunodeficiency virus type 1 binds to 14-3-3 proteins and facilitates complex formation with Cdc25C: implications for cell cycle arrest. J Virol 79:2780–2787PubMedCrossRef

Kogan M, Rappaport J (2011) HIV-1 accessory protein Vpr: relevance in the pathogenesis of HIV and potential for therapeutic intervention. Retrovirology 8:25PubMedCrossRef

Lipton SA (1992) Requirement for macrophages in neuronal injury induced by HIV envelope protein gp120. Neuroreport 3:913–915PubMedCrossRef

Luo X, Carlson KA, Wojna V, Mayo R, Biskup TM, Stoner J, Anderson J, Gendelman HE, Melendez LM (2003) Macrophage proteomic fingerprinting predicts HIV-1-associated cognitive impairment. Neurology 60:1931–1937PubMedCrossRef

Lyons JL, Uno H, Ancuta P, Kamat A, Moore DJ, Singer EJ, Morgello S, Gabuzda D (2011) Plasma sCD14 is a biomarker associated with impaired neurocognitive test performance in attention and learning domains in HIV infection. J Acquir Immune Defic Syndr 57:371–379PubMedCrossRef

Matsuda N, Tanaka H, Yamazaki S, Suzuki J, Tanaka K, Yamada T, Masuda M (2006) HIV-1 Vpr induces G2 cell cycle arrest in fission yeast associated with Rad24/14-3-3-dependent, Chk1/Cds1-independent Wee1 upregulation. Microbes Infect 8:2736–2744PubMedCrossRef

Mhawech-Fauceglia P, Herrmann FR, Andrews C, South S, Beck A, Lele S, Odunsi K (2009) 14-3-3sigma expression and prognostic value in patients with epithelial ovarian carcinoma: a high throughput tissue microarray analysis. Eur J Surg Oncol 35:763–767PubMedCrossRef

Mignon-Ravix C, Cacciagli P, El-Waly B, Moncla A, Milh M, Girard N, Chabrol B, Philip N, Villard L (2010) Deletion of YWHAE in a patient with periventricular heterotopias and pronounced corpus callosum hypoplasia. J Med Genet 47:132–136PubMedCrossRef

Morales D, Acevedo SF, Skolasky RL, Hechavarria R, Santiago S, De La Torre T, Maldonado E, Wojna V (2012a) Translational spatial task and its relationship to HIV-associated neurocognitive disorders and apolipoprotein E in HIV-seropositive women. J Neurovirol 18:488–502PubMedCrossRef

Morales D, Skoulakis EC, Acevedo SF (2012b) 14-3-3s are potential biomarkers for HIV-related neurodegeneration. J Neurovirol 18:341–353PubMedCrossRef

Rackstraw S (2011) HIV-related neurocognitive impairment—a review. Psychol Health Med 16:548–563PubMedCrossRef

Shiga Y, Wakabayashi H, Miyazawa K, Kido H, Itoyama Y (2006) 14-3-3 protein levels and isoform patterns in the cerebrospinal fluid of Creutzfeldt–Jakob disease patients in the progressive and terminal stages. J Clin Neurosci 13:661–665PubMedCrossRef

Torres M, Cartier L, Matamala JM, Hernandez N, Woehlbier U, Hetz C (2012) Altered Prion protein expression pattern in CSF as a biomarker for Creutzfeldt–Jakob disease. PLoS One 7:e36159PubMedCrossRef

Ushijima H, Nishio O, Klocking R, Perovic S, Muller WE (1995) Exposure to gp120 of HIV-1 induces an increased release of arachidonic acid in rat primary neuronal cell culture followed by NMDA receptor-mediated neurotoxicity. Eur J Neurosci 7:1353–1359PubMedCrossRef

Vodicka MA, Koepp DM, Silver PA, Emerman M (1998) HIV-1 Vpr interacts with the nuclear transport pathway to promote macrophage infection. Genes Dev 12:175–185PubMedCrossRef

Wakabayashi H, Yano M, Tachikawa N, Oka S, Maeda M, Kido H (2001) Increased concentrations of 14-3-3 epsilon, gamma and zeta isoforms in cerebrospinal fluid of AIDS patients with neuronal destruction. Clin Chim Acta 312:97–105PubMedCrossRef

Wojna V, Skolasky RL, Hechavarria R, Mayo R, Selnes O, McArthur JC, Melendez LM, Maldonado E, Zorrilla CD, Garcia H, Kraiselburd E, Nath A (2006) Prevalence of human immunodeficiency virus-associated cognitive impairment in a group of Hispanic women at risk for neurological impairment. J Neurovirol 12:356–364PubMedCrossRef

Wojna V, Robles L, Skolasky RL, Mayo R, Selnes O, de la Torre T, Maldonado E, Nath A, Melendez LM, Lasalde-Dominicci J (2007) Associations of cigarette smoking with viral immune and cognitive function in human immunodeficiency virus-seropositive women. J Neurovirol 13:561–568PubMedCrossRef

Xiao T, Ying W, Li L, Hu Z, Ma Y, Jiao L, Ma J, Cai Y, Lin D, Guo S, Han N, Di X, Li M, Zhang D, Su K, Yuan J, Zheng H, Gao M, He J, Shi S, Li W, Xu N, Zhang H, Liu Y, Zhang K, Gao Y, Qian X, Cheng S (2005) An approach to studying lung cancer-related proteins in human blood. Mol Cell Proteomics 4:1480–1486PubMedCrossRef

Zhao LJ, Mukherjee S, Narayan O (1994a) Biochemical mechanism of HIV-I Vpr function. Specific interaction with a cellular protein. J Biol Chem 269:15577–15582PubMed

Zhao LJ, Wang L, Mukherjee S, Narayan O (1994b) Biochemical mechanism of HIV-1 Vpr function. Oligomerization mediated by the N-terminal domain. J Biol Chem 269:32131–32137PubMed

Title: YWHAE/14-3-3ε: a potential novel genetic risk factor and CSF biomarker for HIV neurocognitive impairment
Authors: Diana Morales
Rosa Hechavarria
Valerie Wojna
Summer F. Acevedo
Publication date: 01-10-2013
Publisher: Springer US
Published in: Journal of NeuroVirology / Issue 5/2013
Print ISSN: 1355-0284
Electronic ISSN: 1538-2443
DOI: https://doi.org/10.1007/s13365-013-0200-z

Keynote webinar | Spotlight on medication adherence

Springer Medicine

YWHAE/14-3-3ε: a potential novel genetic risk factor and CSF biomarker for HIV neurocognitive impairment

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 5/2013

Matrix metalloproteinase levels in early HIV infection and relation to in vivo brain status

A novel computerized functional assessment for human immunodeficiency virus-associated neurocognitive disorder

HIV-related cognitive impairment shows bi-directional association with dopamine receptor DRD1 and DRD2 polymorphisms in substance-dependent and substance-independent populations

Dual-mixed HIV-1 coreceptor tropism and HIV-associated neurocognitive deficits

Protective effects of higher cognitive reserve for neuropsychological and daily functioning among individuals infected with hepatitis C

Experimental measles encephalitis in Lewis rats: dissemination of infected neuronal cell subtypes